Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, Ratings reports. Two research analysts have ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), retaining the price target ...

On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...

Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral ...

Barclays analyst Peter Lawson raised the firm’s price target on Biomea Fusion (BMEA) to $11 from $9 and keeps an Equal Weight rating on ...

Biomea Fusion Inc ( (BMEA)) has realeased its Q3 earnings. Here is a breakdown of the information Biomea Fusion Inc presented ...

On Tuesday, Truist Securities adjusted its stance on Biomea Fusion Inc. (NASDAQ:BMEA) stock, moving from a Buy to a Hold rating. This decision comes in the wake of a clinical hold... On Monday, H ...

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...

REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical ...

Deliver a fourth IND candidate in 2025 based on the Biomea FUSION™ Platform technology. Cash, Cash Equivalents, and Restricted Cash: As of September 30, 2024, the Company had cash, cash equivalents ...